Sector Gamma As Has Lifted Abbott Labs (ABT) Stake

December 8, 2017 - By Dolores Ford

Investors sentiment decreased to 0.88 in 2017 Q2. Its down 0.75, from 1.63 in 2017Q1. It fall, as 69 investors sold ABT shares while 545 reduced holdings. 102 funds opened positions while 441 raised stakes. 1.22 billion shares or 0.83% more from 1.21 billion shares in 2017Q1 were reported. Murphy holds 0.16% or 22,042 shares. Price T Rowe Associates Md reported 0.25% in Abbott Laboratories (NYSE:ABT). Villere St Denis J & Communication Limited Liability Corp accumulated 268,200 shares. Northeast Consultants holds 0.08% of its portfolio in Abbott Laboratories (NYSE:ABT) for 4,232 shares. M Kraus & stated it has 2.39% in Abbott Laboratories (NYSE:ABT). Farr Miller & Washington Ltd Limited Liability Company Dc holds 3.46% in Abbott Laboratories (NYSE:ABT) or 727,322 shares. Verity & Verity Ltd Company holds 142,097 shares or 1.96% of its portfolio. Rothschild Asset has 0.01% invested in Abbott Laboratories (NYSE:ABT) for 22,406 shares. Partner Fund LP holds 1.44% in Abbott Laboratories (NYSE:ABT) or 1.10M shares. Private Bancorp reported 0.2% in Abbott Laboratories (NYSE:ABT). Canandaigua Natl Bancorporation holds 36,501 shares. Stephens Ar has invested 0.32% in Abbott Laboratories (NYSE:ABT). Moreover, Endurant Capital LP has 3.45% invested in Abbott Laboratories (NYSE:ABT) for 250,783 shares. Rampart Inv Management Ltd Liability accumulated 21,690 shares. Paloma Prns invested in 0.03% or 48,152 shares.

Since June 15, 2017, it had 0 insider buys, and 1 insider sale for $26,482 activity.

Sector Gamma As increased its stake in Abbott Labs (ABT) by 16.59% based on its latest 2017Q2 regulatory filing with the SEC. Sector Gamma As bought 218,700 shares as the company’s stock declined 3.42% while stock markets rallied. The institutional investor held 1.54M shares of the major pharmaceuticals company at the end of 2017Q2, valued at $74.73 million, up from 1.32 million at the end of the previous reported quarter. Sector Gamma As who had been investing in Abbott Labs for a number of months, seems to be bullish on the $95.19B market cap company. The stock increased 0.05% or $0.03 during the last trading session, reaching $54.69. About 4.42M shares traded. Abbott Laboratories (NYSE:ABT) has risen 15.90% since December 8, 2016 and is uptrending. It has underperformed by 0.80% the S&P500.

More notable recent Abbott Laboratories (NYSE:ABT) news were published by: Investorplace.com which released: “Abbott Laboratories (ABT) a Buy on Strong Quant Score” on November 28, 2017, also Investorplace.com with their article: “High-Level Earnings Momentum Keep Abbott Laboratories (ABT) a Buy” published on November 14, 2017, Investorplace.com published: “Trade of the Day: Abbott Laboratories (ABT)” on November 20, 2017. More interesting news about Abbott Laboratories (NYSE:ABT) were released by: Thestreet.com and their article: “Miles White of Abbott Labs: Cramer’s Top Takeaways” published on November 17, 2017 as well as Investorplace.com‘s news article titled: “Quant Score Make Abbott Laboratories (ABT) a Buy” with publication date: December 05, 2017.

Abbott Laboratories (NYSE:ABT) Ratings Coverage

Among 24 analysts covering Abbott Laboratories (NYSE:ABT), 14 have Buy rating, 0 Sell and 10 Hold. Therefore 58% are positive. Abbott Laboratories had 87 analyst reports since July 24, 2015 according to SRatingsIntel. The stock has “Outperform” rating by RBC Capital Markets on Thursday, January 26. Jefferies maintained the stock with “Buy” rating in Tuesday, September 13 report. The firm has “Hold” rating by BMO Capital Markets given on Thursday, July 20. RBC Capital Markets maintained the shares of ABT in report on Thursday, July 23 with “Outperform” rating. The firm has “Buy” rating given on Monday, June 26 by RBC Capital Markets. As per Saturday, August 29, the company rating was maintained by Deutsche Bank. Jefferies maintained the shares of ABT in report on Tuesday, October 10 with “Buy” rating. The firm has “Equal-Weight” rating by Morgan Stanley given on Tuesday, July 11. BMO Capital Markets downgraded Abbott Laboratories (NYSE:ABT) on Tuesday, March 14 to “Market Perform” rating. Cowen & Co maintained the stock with “Buy” rating in Friday, September 22 report.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.